Condition: AL Amyloidosis · Sponsor: SWOG Cancer Research Network
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. The stem cells are then returned to the patients to replace the blood forming cells that were destroyed by the chemotherapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs, such as cyclophosphamide and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to lower the body's immune response to help stop the growth of cancer cells. Giving a stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in patients with newly diagnosed AL amyloidosis.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| CTCA at Western Regional Medical Center | Goodyear, Arizona, United States | Recruiting |
| Banner University Medical Center - Tucson | Tucson, Arizona, United States | Recruiting |
| University of Arizona Cancer Center-North Campus | Tucson, Arizona, United States | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine, California, United States | Recruiting |
| City of Hope at Irvine Lennar | Irvine, California, United States | Recruiting |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| Smilow Cancer Hospital-Derby Care Center | Derby, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center at Greenwich | Greenwich, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center - Guilford | Guilford, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center at Saint Francis | Hartford, Connecticut, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
+ 105 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06022939